Safety and IOP-Lowering Effects of WB007

Completed · Phase 1/Phase 2

Conditions studied: Glaucoma, Primary Open Angle, Ocular Hypertension

In brief

The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study. Part 1 was a 3-period dose escalation that evaluated 3 concentrations of WB007 ophthalmic solution following a single dose in one eye. Part 2 was a randomized, double-masked, parallel comparison that evaluated two concentrations of WB007 (selected based on Part 1 results) in both eyes compared with timolol 0.5% for 14 days.

Key facts

Study ID

NCT04149899

Run by

Bausch & Lomb Incorporated

People needed

77

Starts

2019-11-14

Expected to finish

2022-12-14

Last updated by the study team

2025-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ocular hypertension or primary open-angle glaucoma in each eye

You may not qualify if…

• History of orthostatic hypotension
• Any active ocular disease
• Anticipated wearing of contact lenses during study
• Contraindication to pupil dilatation

Where it is running

• Eye Research Foundation — Newport Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.